Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients

Nucleosides, Nucleotides and Nucleic Acids

Volumn 29, Issue 4-6, 2010, Pages 321-324

  Ogata, N ^a   Fujimori, S ^a   Oka, Y ^a   Kaneko, K ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

dyslipidemia; LDL cholesterol; Statin; uric acid

Indexed keywords

ATORVASTATIN; PITAVASTATIN; ROSUVASTATIN; URIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; URIC ACID BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIMIDINES; PYRROLES; QUINOLINES; SULFONAMIDES; URIC ACID;

EID: 77953702031     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257771003741323     Document Type: Article

References (4)

1. Feig, D.I.; Kang, D.H.; Johnson, R.J. Uric acid and cardiovascular risk. N. Engl. J. Med. 2008, 359, 1811-1821.
2. Athyros, V.G.; Elisaf, M.; Papageorgiou, A.A.; Symeonidis, A.N.; Pehlivanidis, A.N.; Bouloukos, V.I.; Milionis, H.J.; Mikhailidis, D.P. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am. J. Kidney. Dis. 2004, 43, 589-599. (Pubitemid 38401873)
3. Milionis, H.J.; Rizos, E.; Kostapanos, M.; Filippatos, T.D.; Gazi, I.F.; Ganotakis, E.S.; Goudevenos, J.; Mikhailidis, D.P.; Elisaf, M.S. Treating to target patients with primary hyperlipidemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr. Med. Res. Opin. 2006, 22, 1123-1131.
4. Huggins, G.S.; Pasternak, R.C.;Alpert, N.M.; Fischman,A.J.; Gewirtz, H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 1998, 98, 1291-1296.